The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Previous research has shown that untreated insomnia has significant direct and indirect burden. Despite the high comorbidity of insomnia and Major Depressive Disorder (MDD), no studies have attempted to determine the economic costs among patients diagnosed with MDD and insomnia. The purpose of this study was to estimate the economic burden of comorbid untreated insomnia within an adult and elderly population with MDD. DESIGN: A retrospective, observational study comparing direct health care costs in insomnia patients with MDD to a matched non-insomniacs group with MDD that had MDD and no insomnia. Data was from taken from managed care claims database in the United States. MEASUREMENTS AND RESULTS: A large managed care claims database was used to identify MDD subjects (aged >or=18 years) anytime between 01/01/1998 to 11/30/2007 using MDD-specific ICD-9-CM diagnoses. Insomniacs with MDD (n = 38,213) were selected from this cohort using insomnia-specific ICD-9-CM codes or hypnotic use. Costs were calculated for the twelve months prior to initiating insomnia treatment/diagnosis. Direct costs were compared with 1:1 matched non-insomniacs with MDD. Total direct costs included inpatient, outpatient, emergency room (ER) and drug costs. Cost outcomes were analyzed using a generalized linear model with gamma distribution and log link, and GEE estimation. Insomniacs with MDD had statistically greater (p < 0.01) total outpatient visits 8.34 (SE = 0.04) vs non-insomniacs with MDD 7.26 (SE = 0.04); MDD-related visits 3.9 (SE = 0.04) vs non-insomniacs with MDD 2.1 (SE = 0.02); and antidepressant prescriptions 5.0 (SE = 0.03) vs non-insomniacs with MDD 4.2 (SE = 0.03). Overall direct costs for insomniacs with MDD were significantly (p < 0.001) higher than non-insomniacs with MDD ($4858 vs $4007). Similar direct cost differences ($1007) were found in a sample of elderly (aged >or=65 years) patients (n = 2756) mean age = 75.6 yrs. CONCLUSIONS: Untreated insomnia within an adult and elderly comorbid MDD population is associated with higher MDD-related and overall direct costs compared to MDD without insomnia. Key limitations associated with this study make it likely that the direct costs and appearance of comorbidities may have been underestimated. These include that: the non-insomnia with MDD group may have untreated/undiagnosed insomnia; some identified cases were likely treated with over-the-counter or behavioral treatment; and that other drugs may have been used for insomnia were not considered for this study and may have been taken for another condition. Future research needs to determine whether treating comorbid insomnia within a MDD population is cost-effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Health care costs associated with depressive and anxiety disorders in primary care
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.3.352 · Cited by 555
Fava, M., McCall, W. V., Krystal, A., Wessel, T., Rubens, R., Caron, J., Amato, D., & Roth, T. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.016 · Cited by 480
Residual symptoms in depressed patients who respond acutely to fluoxetine
Nierenberg, A. A., Keefe, B. R., Leslie, V. C., Alpert, J. E., Pava, J. A., Worthington, J. J., Rosenbaum, J. F., & Fava, M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0403 · Cited by 470
Buysse, D. J., Reynolds, C. F., Kupfer, D. J., Thorpy, M. J., Bixler, E., Manfredi, R., Kales, A., Vgontzas, A., Stepanski, E., Roth, T., et al. (1994) · Sleep · doi:10.1093/sleep/17.7.630 · Cited by 274
Cited by
Health economics of insomnia treatments: The return on investment for a good night's sleep
Wickwire, E. M., Shaya, F. T., & Scharf, S. M. (2016) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2015.11.004 · Cited by 287
Wickwire, E. M., Tom, S. E., Scharf, S. M., Vadlamani, A., Bulatao, I. G., & Albrecht, J. S. (2019) · Sleep · doi:10.1093/sleep/zsz007 · Cited by 139
“This design, common in the insomnia literature [22, 25, 28, 31], is predicated on the understanding that insomnia is a chronic condition, and most insomnia patients have had the condition for years prior to diagnosis or treatment [32, 33].”
BackgroundResultHogan, M.-E., Taddio, A., Katz, J., Shah, V., & Krahn, M. (2016) · Pain · doi:10.1097/j.pain.0000000000000561 · Cited by 105
Psychiatric comorbidities in patients with major depressive disorder
Ittasakul, P., Thaipisuttikul, P., Waleeprakhon, P., Wisajun, P., & Jullagate, S. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s72026 · Cited by 99
Cheng, P., Casement, M. D., Kalmbach, D. A., Castelan, A. C., & Drake, C. L. (2021) · Sleep · doi:10.1093/sleep/zsaa258 · Cited by 97
Self-citation
Metadata
- Authors
- Asche, C. V., Joish, V. N., Camacho, F., & Drake, C. L.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2010-06
- Volume
- 26
- Issue
- 8
- Pages
- 1843-1853
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2054864346
- Cited by
- 43
- References
- 5
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder. https://app.cochat.ai/papers/10.1185/03007995.2010.488037
- The paper
- Asche, C. V., Joish, V. N., Camacho, F., & Drake, C. L. (2010). The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder. Current Medical Research and Opinion. https://doi.org/10.1185/03007995.2010.488037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.